Amyris Inc. (NASDAQ:AMRS) was the recipient of a large decline in short interest in November. As of November 15th, there was short interest totalling 5,761,321 shares, a decline of 25.5% from the October 31st total of 7,731,396 shares. Based on an average daily trading volume, of 3,929,795 shares, the days-to-cover ratio is presently 1.5 days. Currently, 4.1% of the company’s stock are sold short.

A number of brokerages have recently issued reports on AMRS. Zacks Investment Research lowered shares of Amyris from a “buy” rating to a “hold” rating in a research note on Wednesday, October 19th. Singular Research restated a “buy” rating and issued a $2.80 target price on shares of Amyris in a research note on Wednesday, September 28th.

Shares of Amyris (NASDAQ:AMRS) opened at 0.8068 on Monday. The company’s market cap is $212.20 million. Amyris has a 12 month low of $0.31 and a 12 month high of $1.81. The company’s 50 day moving average is $0.87 and its 200-day moving average is $0.57.

Amyris (NASDAQ:AMRS) last posted its earnings results on Wednesday, November 2nd. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by $0.01. The company had revenue of $26.50 million for the quarter, compared to analyst estimates of $33.61 million. During the same quarter in the previous year, the firm earned ($0.23) EPS. The company’s revenue was up 208.1% compared to the same quarter last year. Analysts expect that Amyris will post ($0.25) EPS for the current fiscal year.

In other news, major shareholder (Mauritius) Pte Ltd Maxwell sold 2,611,233 shares of the company’s stock in a transaction dated Friday, November 4th. The shares were sold at an average price of $0.89, for a total value of $2,323,997.37. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 48.70% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Jacobs Levy Equity Management Inc. purchased a new position in Amyris during the first quarter worth about $269,000. KBC Group NV raised its position in Amyris by 330.1% in the third quarter. KBC Group NV now owns 329,101 shares of the company’s stock worth $191,000 after buying an additional 252,589 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in Amyris by 22.4% in the second quarter. Vanguard Group Inc. now owns 1,701,779 shares of the company’s stock worth $766,000 after buying an additional 311,142 shares during the last quarter. Institutional investors and hedge funds own 35.83% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Amyris Inc. (AMRS) Short Interest Update” was published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are accessing this news story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The original version of this news story can be accessed at

Amyris Company Profile

Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.

5 Day Chart for NASDAQ:AMRS

Receive News & Stock Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related stocks with our FREE daily email newsletter.